Coresh Josef, Hu Jiun-Ruey, Bello Aminu K, Feldman Harold I, Fogo Agnes B, Ganji Mohammad Reza, Harris David C, Levey Andrew S, Okpechi Ikechi G, Stengel Benedicte, Thomas Bernadette, Wiecek Andrzej, Gansevoort Ron T
Johns Hopkins University Bloomberg School of Public Health, George W. Comstock Center for Public Health Research and Prevention, Baltimore, Maryland, USA.
Johns Hopkins University School of Medicine, Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, Maryland, USA.
Kidney Int Suppl (2011). 2017 Oct;7(2):63-70. doi: 10.1016/j.kisu.2017.07.002. Epub 2017 Sep 20.
Chronic kidney disease (CKD) continues to remain high globally, up to 13.4% by one estimate. Although the number, geographic distribution, size, and quality of the studies examining CKD prevalence and incidence have increased over the past decade, the global capacity for CKD surveillance is still far less developed than that for hypertension, diabetes, and cardiovascular disease. Estimating CKD prevalence is constrained by inadequate standardization of serum creatinine and urine albumin assays, heterogeneity in study designs, lack of national registries in many countries, incomplete adoption of disease classification guidelines, and inconsistent use of evidence-based equations for estimating glomerular filtration rate. Goal 1: Improve monitoring of CKD prevalence. To achieve this, disseminate the rationale for CKD prevalence monitoring, achieve uniform measurement of CKD markers, promote inclusion of CKD measurements in all large chronic disease cohorts and health surveys, harness administrative claims data for CKD surveillance, and incorporate the new CKD classification system in the International Classification of Diseases. Goal 2: Improve CKD monitoring of populations underrepresented in studies to date. To achieve this, establish registries of chronic dialysis and transplantation in all countries; establish registries for special CKD groups, such as children, patients with rare diseases, and patients with special etiologies of CKD. Goal 3: Improve identification of individuals with CKD. To achieve this, implement the Kidney Disease: Improving Global Outcomes guidelines for screening and testing, carry out randomized studies on screening strategies, ensure that estimated glomerular filtration rate is reported with all reports of serum creatinine, and leverage new software for identification and follow-up of CKD cases.
慢性肾脏病(CKD)在全球的发病率持续居高不下,据一项估计高达13.4%。尽管在过去十年中,研究CKD患病率和发病率的研究数量、地理分布、规模及质量都有所增加,但全球CKD监测能力仍远不如高血压、糖尿病和心血管疾病的监测能力发达。估算CKD患病率受到血清肌酐和尿白蛋白检测标准化不足、研究设计的异质性、许多国家缺乏国家登记系统、疾病分类指南采用不完整以及估算肾小球滤过率的循证方程使用不一致等因素的限制。目标1:改善CKD患病率监测。为此,传播CKD患病率监测的基本原理,实现CKD标志物的统一测量,促进在所有大型慢性病队列和健康调查中纳入CKD测量,利用行政索赔数据进行CKD监测,并将新的CKD分类系统纳入国际疾病分类。目标2:改善对迄今研究中代表性不足人群的CKD监测。为此,在所有国家建立慢性透析和移植登记系统;为特殊CKD群体建立登记系统,如儿童、罕见病患者和具有特殊CKD病因的患者。目标3:改善CKD个体的识别。为此,实施《改善全球肾脏病预后》筛查和检测指南,开展筛查策略的随机研究,确保在所有血清肌酐报告中报告估算肾小球滤过率,并利用新软件对CKD病例进行识别和随访。